Skip to main content
QMSQMS
QMS
  • Welcome to your QMS
  • Quality Manual
  • Procedures
  • Records
    • GP-001 Documents and records control
    • GP-002 Quality planning
    • GP-003 Audits
    • GP-004 Vigilance system
    • GP-005 HR and training
    • GP-007 Post-market surveillance
    • GP-009 Sales
      • T-009-001
      • R-009-001 Implementation plans
        • R-009-001 Iderma 20230301
        • R-009-001 Sermas 20230301
        • R-009-001 Galderma 20230727
        • R-009-001 Boehringer Ingelheim 20240207
        • R-009-001 Hospital del Mar 20240709
        • R-009-001 ES Boehringer Ingelheim 20241223
        • R-009-001 ES Generalitat Valenciana licitacion contrato menor 20250107
        • R-009-001 ES Licitación SESPA 20250101
        • R-009-001 US Sagimet ICON 20250113
        • R-009-001 ES Sandoz 20250407
        • R-009-001 US Johnson & Johnson 20250505
        • R-009-001 US J&J 20250612
        • R-009-001 BR J&J 20250822
        • R-009-001 ES Aptima 20250911
        • R-009-001 Implementation Plan: Visiba Integration Enhancement
        • R-009-001 FR AbbVie Calculators 20250926
        • R-009-001 US Johnson & Johnson 20251031
        • R-009-001 ES Novartis 20251104
        • R-009-001 UK Pfizer 20260107
        • R-009-001 PL LUX MED Bupa 20260225
        • R-009-001 IT Chiesi Epidermolisis Bullosa 2026
        • R-009-001 PT Lusíadas 2026
        • R-009-001 US Johnson & Johnson Clinical Trial - AD Biopsy Images Add On
        • R-009-001 ES Telefónica - Aragón (Phase 1)
        • R-009-001 PT CUF Hospitais 2026
        • R-009-001 ES Novartis 20260331
        • R-009-001 FR Quantificare Sanofi AD Clinical Trials 20260505
          • Internal Project Tracker: FR Quantificare Sanofi AD Clinical Trials Retrospective
    • GP-010 Suppliers
    • GP-011 Provision of service
    • GP-012 Design, Redesign and Development
    • GP-018 Infrastructure and facilities
    • GP-019 Non-product software validation
    • GP-023 Change control management
    • GP-030 Cyber Security Management
    • GP-031 Training Data Governance
    • GP-050 Data Protection
    • GP-051 Security violations
    • GP-052 Data Privacy Impact Assessment (DPIA)
    • GP-110 Esquema Nacional de Seguridad
    • GP-200 Remote Data Acquisition in Clinical Investigations
    • GP-600 Equality Planning
  • Legit.Health Plus Version 1.1.0.0
  • Legit.Health Plus Version 1.1.0.1
  • Legit.Health version 2.1 (Legacy MDD)
  • Legit.Health US Version 1.1.0.0
  • Legit.Health Utilities
  • Licenses and accreditations
  • Applicable Standards and Regulations
  • BSI Non-Conformities
  • Pricing
  • Public tenders
  • Trainings
  • Records
  • GP-009 Sales
  • R-009-001 Implementation plans
  • R-009-001 FR Quantificare Sanofi AD Clinical Trials 20260505
  • Internal Project Tracker: FR Quantificare Sanofi AD Clinical Trials Retrospective

Internal Project Tracker: FR Quantificare Sanofi AD Clinical Trials Retrospective

  • Deal Id: 60028458866
  • Deal name: FR Quantificare - Sanofi: AI Photo Analysis Proof of Concept Study

This document tracks internal meetings and decisions for the Quantificare/Sanofi AI Photo Analysis Proof of Concept Study.

Reference Documents​

DateDocument
2026-05-05AI Image Analysis Project Description (APR-20 draft) — DK

Meeting History​

DateTypeTopicsKey Highlights
2026-05-07InternalEASI Global viabilityDiscuss whether EASI Global can be supported — affected area must be calculated by BSA

2026-05-07 Internal Meeting​

Objective: Assess the technical viability of supporting EASI Global scoring, specifically whether the affected area component can be calculated from photographs using BSA estimation.

Topics Discussed​

EASI Global Viability​

  • EASI Global requires an affected area score per body region, which depends on Body Surface Area (BSA) estimation from photographs.
  • Open question: can the device reliably calculate BSA from the available images?

Next Steps (2026-05-07)​

  • TBC
Previous
R-009-001 FR Quantificare Sanofi AD Clinical Trials 20260505
Next
GP-010 Suppliers
  • Reference Documents
  • Meeting History
  • 2026-05-07 Internal Meeting
    • Topics Discussed
      • EASI Global Viability
    • Next Steps (2026-05-07)
All the information contained in this QMS is confidential. The recipient agrees not to transmit or reproduce the information, neither by himself nor by third parties, through whichever means, without obtaining the prior written permission of Legit.Health (AI Labs Group S.L.)